VIDEO: Tyrosine kinase inhibitors offer new mechanism of action for VEGF inhibition
Click Here to Manage Email Alerts
In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute discusses how tyrosine kinase inhibitors differ from other treatment options for retinal diseases.
“The tyrosine kinase inhibitors represent a new mechanism of action where these TKIs — vorolanib, sunitinib and axitinib — actually act intracellularly to act as pan-VEGF, FGF and PDGF inhibitors, where they block all of the receptors for the VEGF family,” he said.
Sharma also summarized key findings from the DAVIO 2 trial investigating EYP-1901 (vorolanib intravitreal insert, EyePoint Pharmaceuticals) for the treatment of wet age-related macular degeneration.
Collapse
Sharma S, et al. Comparison of tyrosine kinase inhibitors being developed for intravitreal delivery; and clinical efficacy of EYP-1901 (vorolanib intravitreal insert), a pan–VEGF receptor inhibitor, in the DAVIO 2 study for wet age-related macular degeneration (wAMD). Presented at: Retina Society meeting; Sept. 11-15, 2024; Lisbon, Portugal.
Read more about
Click Here to Manage Email Alerts